Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 24, 26 | -0.23 Increased by +8.00% | -0.18 Decreased by -27.78% |
| Nov 12, 25 | -0.20 Increased by +17.08% | -0.20 |
| Aug 12, 25 | -0.24 Decreased by -9.09% | -0.21 Decreased by -14.29% |
| May 12, 25 | -0.21 Increased by +4.55% | -0.22 Increased by +5.96% |
| Mar 19, 25 | -0.25 Increased by 0.00% | -0.22 Decreased by -11.71% |
| Nov 12, 24 | -0.24 Decreased by -0.50% | -0.21 Decreased by -14.86% |
| Aug 14, 24 | -0.22 Increased by +51.11% | -0.19 Decreased by -15.79% |
| May 14, 24 | -0.22 Increased by +15.38% | -0.21 Decreased by -4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 650.00 K Decreased by -2.26% | -29.56 M Decreased by -2.00% | Decreased by -4.55 K% Decreased by -4.35% |
| Sep 30, 25 | 378.00 K Decreased by -77.78% | -28.71 M Decreased by -4.77% | Decreased by -7.59 K% Decreased by -371.48% |
| Jun 30, 25 | 593.00 K Decreased by -53.31% | -30.57 M Decreased by -23.51% | Decreased by -5.15 K% Decreased by -164.52% |
| Mar 31, 25 | 1.18 M Increased by +31.29% | -26.35 M Decreased by -19.89% | Decreased by -2.23 K% Increased by +8.68% |
| Dec 31, 24 | 665.00 K Increased by +96.75% | -28.98 M Decreased by -23.10% | Decreased by -4.36 K% Increased by +37.43% |
| Sep 30, 24 | 1.70 M Increased by +128.63% | -27.40 M Decreased by -24.57% | Decreased by -1.61 K% Increased by +45.51% |
| Jun 30, 24 | 1.27 M Decreased by -62.28% | -24.75 M Increased by +40.61% | Decreased by -1.95 K% Decreased by -57.46% |
| Mar 31, 24 | 898.00 K Decreased by -29.24% | -21.98 M Increased by +5.91% | Decreased by -2.45 K% Decreased by -32.96% |